<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276536</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-3575</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-3575</secondary_id>
    <nct_id>NCT00276536</nct_id>
  </id_info>
  <brief_title>Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma</brief_title>
  <acronym>IFNa</acronym>
  <official_title>Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth&#xD;
      of cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in&#xD;
      treating patients with stage IV solid tumors, lymphoma, or myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Confirm tolerance and safety of interferon alfa-1b (IFN-α1b) in patients with stage IV&#xD;
           solid tumors, lymphoma, or myeloma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of IFN-α1b given daily by subcutaneous&#xD;
           injection in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive interferon alfa-1b subcutaneously once daily for at least 1 month. Treatment&#xD;
      continues for up to 12 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of interferon alfa-1b until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance and safety as measured by any ≥ Grade IV granulocyte toxicity or any Grade III toxicity thought to be drug related at 1 week after each course</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Melanoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alpha-1b</intervention_name>
    <description>interferon</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Interferon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN</intervention_name>
    <description>IFN daily</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Interferon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy, including, but not limited to, renal cell&#xD;
             carcinoma, melanoma, Kaposi's sarcoma, breast carcinoma, lymphoma, myeloma, or tumors&#xD;
             of endothelial origin&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
               -  Refractory to standard therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Evaluable disease can include clinically or radiographically nonmeasurable tumor&#xD;
                  or specific tumor markers&#xD;
&#xD;
          -  Patients with prior solitary CNS metastasis allowed&#xD;
&#xD;
               -  Must have had prior definitive therapy ≥ 3 months previously&#xD;
&#xD;
               -  No requirement for glucocorticoids unless for physiologic replacement&#xD;
&#xD;
          -  No multiple CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.3 times upper limit of normal (ULN) OR&#xD;
&#xD;
          -  Creatinine clearance of 60 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 1.3 times ULN&#xD;
&#xD;
          -  AST ≤ 5 times ULN&#xD;
&#xD;
          -  No pregnant or lactating women&#xD;
&#xD;
          -  Fertile women and men, unless surgically sterile, must use effective contraception&#xD;
&#xD;
          -  No history of serious cardiac arrhythmia or cardiac arrhythmia requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class III or IV disease&#xD;
&#xD;
          -  No other severe cardiovascular disease&#xD;
&#xD;
          -  No known seizure disorder&#xD;
&#xD;
          -  No known HIV or hepatitis B surface antigen positivity&#xD;
&#xD;
          -  No active clinical infection requiring antibiotics within the past 7 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 months since prior interferon therapy and/or ≤ 400 million units of&#xD;
             interferon&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery requiring general anesthesia&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy or chemotherapy&#xD;
&#xD;
          -  Treatment with hormones or other chemotherapeutic agents may not be administered&#xD;
             except for steroids given for preexisting adrenal failure or hormones administered for&#xD;
             nondisease-related conditions (e.g., insulin for diabetes)&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  No concurrent dexamethasone, other steroidal antiemetics, or anti-inflammatories&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-5044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>October 11, 2015</last_update_submitted>
  <last_update_submitted_qc>October 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon-alfa-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

